HTLV-1 and HTLV-2 are two closely related retroviruses that infect human T cells and, once acquired, persist for life. HTLV-1 is the more consequential of the pair: it causes a rare but aggressive blood cancer called adult T-cell leukemia/lymphoma (ATL) and a debilitating spinal cord disease known as HAM/TSP. HTLV-2, despite sharing much of the same genetic architecture, has never been definitively linked to cancer and causes neurological problems far less often. The gap in disease severity between two viruses that look so similar on paper is one of the more puzzling questions in retrovirology, and it shapes everything from how these infections are transmitted to how they are screened for, managed, and studied.
How HTLV-1 and HTLV-2 Spread
Both viruses share the same three routes of transmission: sexual contact, mother-to-child transfer (mainly through breastfeeding), and exposure to infected blood, whether through shared needles or transfusion. Unlike HIV, HTLV does not spread efficiently through free virus particles in body fluids. Instead, it travels inside infected lymphocytes, meaning transmission generally requires the transfer of living cells from one person to another.
Sexual transmission accounts for the majority of adult HTLV-1 cases, particularly in areas where the virus is not deeply endemic in the general population.1PubMed Central. HTLV-1 Is Also a Sexually Transmitted Infection A prospective study tracking the partners of HTLV carriers found a transmission rate of roughly 0.6 per 100 person-years, with no significant difference between HTLV-1 and HTLV-2.2The Journal of Infectious Diseases. A Prospective Study of Sexual Transmission of Human T Lymphotropic Virus Type I and Type II That rate is low for any single encounter, but over years of unprotected sex with an infected partner the cumulative risk adds up. Male-to-female transmission appears somewhat more efficient, though the same study found that female-to-male spread may play a larger role than previously assumed. Risk factors include having many lifetime sexual partners, concurrent sexually transmitted infections, and especially syphilis, which roughly doubled or tripled the odds of HTLV-1 infection in both men and women in an endemic Caribbean population.3PubMed. Sexual transmission of human T-lymphotropic virus type I (HTLV-I)
Mother-to-child transmission is the other major route, and it works differently than with HIV. Transplacental spread and transmission during delivery are uncommon. The virus passes primarily through breast milk, with longer breastfeeding and higher maternal viral load increasing the risk.4PubMed Central. Mother-to-Child Transmission of Human T-Cell Lymphotropic Viruses-1/2: What We Know, and What Are the Gaps in Understanding and Preventing This Route of Infection A meta-analysis found a fourfold difference in infant infection rates between breastfed babies (about 17.5%) and exclusively formula-fed babies (about 4.3%), and avoiding breastfeeding altogether prevented an estimated 85% of mother-to-child transmissions.5PubMed Central. Current Interventions to Prevent HTLV-1 Mother-to-Child Transmission and Their Effectiveness: A Systematic Review and Meta-Analysis Japan, Brazil, and several other countries now recommend that HTLV-1-positive mothers avoid breastfeeding or limit it to a short duration.
Sharing needles is the main driver of HTLV-2 spread. In parts of the Americas, HTLV-2 has been endemic in indigenous populations for thousands of years, and from those communities it has moved into injection drug-using networks. A study of injection drug users in Washington State found that about 7.4% were infected with HTLV-2.6PubMed Central. HTLV-2 infection in injection drug users in King County, Washington Blood transfusion was historically a concern for both viruses, but routine screening of donated blood in most high-income countries has nearly eliminated that route. Leukoreduction, the filtering of white blood cells from donated blood, is thought to further reduce HTLV transmission, though rigorous data on exactly how effective it is remain scarce.7PubMed Central. Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety
Where These Viruses Are Found
HTLV-1 infects an estimated 5 to 10 million people worldwide, though exact numbers are uncertain because many endemic regions lack robust screening programs. The virus clusters in pockets of high prevalence that can sit right next to areas where it is nearly absent. The main endemic zones include southwestern Japan, sub-Saharan Africa, South America, the Caribbean, parts of the Middle East, and Australo-Melanesia.8PubMed Central. Epidemiological Aspects and World Distribution of HTLV-1 Infection In many of these regions, prevalence rises with age and is higher in women than men, consistent with sexual transmission accumulating over a lifetime.
HTLV-2 has a different geographic profile. It is widespread among indigenous peoples of the Americas and is considered ancestral to those populations. The Brazilian Amazon, in particular, is the largest endemic area in the world for HTLV-2.9PubMed Central. Origin and prevalence of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) among indigenous populations in the Americas Outside of indigenous communities, HTLV-2 is found mainly among people who inject drugs in North America, South America, and Europe.
What HTLV-1 Does to the Body
Most people infected with HTLV-1 never develop a serious illness. The virus quietly integrates into the DNA of T cells and persists through the division of those cells rather than through active viral replication in the bloodstream. But in a small fraction of carriers, two major diseases can emerge, sometimes decades after the initial infection.
Adult T-Cell Leukemia/Lymphoma
ATL is a cancer of mature T cells that occurs in roughly 3 to 5% of people infected with HTLV-1 over a lifetime, typically appearing 20 to 60 years after infection. It comes in four recognized clinical subtypes: acute, lymphoma, chronic, and smoldering.10PubMed Central. Adult T-Cell Leukemia/Lymphoma The smoldering and chronic forms progress slowly and are often managed with careful monitoring until they worsen, much like certain indolent lymphomas.11PubMed Central. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting The acute and lymphoma forms, which are more common, carry one of the worst prognoses among blood cancers. Historically, the median survival for the acute subtype was about six months, and for the lymphoma subtype about ten months.12PubMed Central. Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma These grim numbers reflect both the inherent drug resistance of ATL cells and the deep immunosuppression that accompanies the disease, which makes patients vulnerable to severe infections.
HAM/TSP
HTLV-1-associated myelopathy, also known as tropical spastic paraparesis, is a progressive disease of the spinal cord. It affects a similar fraction of HTLV-1 carriers as ATL but tends to develop somewhat sooner after infection. The immune system’s aggressive response to HTLV-1-infected cells in the central nervous system drives chronic inflammation that damages the spinal cord over time.13PubMed. Th17/IL-17 Axis in HTLV-1-Associated Myelopathy Tropical Spastic Paraparesis and Multiple Sclerosis: Novel Insights into the Immunity During HAMTSP Symptoms typically start with stiffness and weakness in the legs, progressing to difficulty walking and, in many cases, dependence on a wheelchair. Bladder dysfunction is especially common: a large Japanese registry study found that over 90% of HAM/TSP patients had urinary symptoms, and roughly a quarter needed catheters.14PubMed Central. Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan
Other Inflammatory Conditions
Beyond ATL and HAM/TSP, HTLV-1 is linked to a range of inflammatory conditions that are less well known but can meaningfully affect quality of life. These include uveitis (inflammation inside the eye), a Sjögren-like dry-eye and dry-mouth syndrome, inflammatory skin conditions such as infective dermatitis, interstitial lung disease, inflammatory arthritis, and thyroid disorders including Hashimoto’s thyroiditis.15PubMed. Inflammatory manifestations of HTLV-1 and their therapeutic options These conditions can appear in carriers who never develop ATL or HAM/TSP and are thought to reflect the same underlying immune dysregulation the virus causes.
What HTLV-2 Does (and Doesn’t Do)
HTLV-2 has never been definitively linked to a lymphoproliferative cancer the way HTLV-1 has been linked to ATL.16Retrovirology. Comparative virology of HTLV-1 and HTLV-2 That does not mean the virus is entirely harmless, but its clinical impact is far more subtle. A study comparing HTLV-1 and HTLV-2-infected individuals to uninfected controls found that both groups had higher rates of leg weakness, impaired balance, abnormal reflexes, reduced vibration sense, and urinary incontinence than uninfected people.17PubMed Central. Neurologic abnormalities in HTLV-I– and HTLV-II–infected individuals without overt myelopathy In other words, HTLV-2 carriers can have mild neurological findings even without a formal HAM/TSP diagnosis.
Rare cases of a HAM/TSP-like illness have been reported in HTLV-2-positive individuals. The earliest well-documented case involved two sisters with a neurodegenerative syndrome resembling a form of multiple system atrophy.18The Lancet. Chronic neurodegenerative disease associated with HTLV-II infection However, many reported neurological problems in HTLV-2 carriers are difficult to disentangle from the effects of concurrent HIV infection or the health consequences of injection drug use, which is the most common route of HTLV-2 acquisition.19PubMed. Human T-lymphotropic virus type II and neurological disease
Why Two Similar Viruses Cause Such Different Diseases
The genomes of HTLV-1 and HTLV-2 are organized in much the same way, yet HTLV-1 causes cancer and serious neurological disease far more often. One major clue lies in which type of T cell each virus preferentially transforms. In the lab, HTLV-1 ends up driving the expansion of CD4+ T cells (the immune cells commonly called “helper T cells”), while HTLV-2 tends to expand CD8+ T cells (“killer T cells”). Researchers traced this difference to the viral envelope protein: swapping the envelope gene between the two viruses reversed their cellular preferences.20PubMed Central. Envelope is a major viral determinant of the distinct in vitro cellular transformation tropism of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2
Interestingly, the preference for one T cell type over the other does not appear at the moment of initial infection. In a rabbit model, both viruses were detected in CD4+ and CD8+ cells within a week. It was only over the following weeks that one cell type came to dominate, suggesting that the tropism is a result of selective clonal expansion after infection rather than a preference during viral entry.21PubMed Central. Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion Because ATL is specifically a cancer of CD4+ T cells, this post-infection divergence likely explains a great deal about why HTLV-1, and not HTLV-2, is linked to leukemia.
Getting Tested
HTLV infection is usually detected through a two-step process. The first step is a screening blood test that looks for antibodies against the virus, typically using an enzyme immunoassay or a chemiluminescence-based assay. These tests are sensitive but not perfect: they can produce false positives, particularly in populations where the virus is rare, and they cannot reliably distinguish HTLV-1 from HTLV-2 because the two viruses share many of the same proteins.22PubMed Central. A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
Positive screening results are followed by a confirmatory test. Western blot has traditionally filled this role, using type-specific envelope proteins to differentiate HTLV-1 from HTLV-2. However, Western blot produces a frustrating number of “indeterminate” results, where the antibody pattern is not clear enough to confirm or rule out infection. Newer line immunoassays have been replacing Western blot in some countries, and molecular testing using PCR can both confirm infection and determine the viral type. In Japan, a diagnostic algorithm combining a line immunoassay with PCR for indeterminate cases has been adopted as the most reliable approach.23PubMed Central. Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting In Brazil, a different strategy has been proposed: using two screening immunoassays followed by real-time PCR for confirmation, which cuts costs while improving the ability to distinguish between the two virus types.24Journal of Virological Methods. The best algorithm to confirm the diagnosis of HTLV-1 and HTLV-2 in at-risk individuals from São Paulo, Brazil
In many countries, however, there is no routine screening at all outside of blood donation. England and Wales offer a case in point: modeling suggests that targeted antenatal screening of high-risk pregnant women could prevent roughly 58 infant infections per year while actually saving money compared to no screening.25Eurosurveillance. Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021 The fact that such screening is not yet widespread globally reflects a broader pattern of neglect: HTLV-1 has been called one of the most overlooked pathogens in global public health.
Treatment Options
There is no cure for HTLV-1 or HTLV-2 infection. The virus integrates into host cell DNA and persists indefinitely. Treatment is directed at the diseases the virus causes rather than the virus itself.
Treating ATL
For the aggressive forms of ATL (acute and lymphoma subtypes), standard treatment involves multi-agent chemotherapy, ideally followed by a bone marrow transplant from a donor if the patient is a candidate. The combination of interferon-alpha and zidovudine (an antiviral originally developed for HIV) is also a standard option, particularly for the leukemic forms of the disease. A meta-analysis found that the interferon-alpha/zidovudine regimen achieved an overall response rate of about 67%, with a complete response in roughly a third of patients and a partial response in another third.26PubMed Central. Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis Patients who received this regimen early in their treatment and in combination with chemotherapy tended to do better than those who received it alone. In Japan, newer targeted drugs including mogamulizumab (a monoclonal antibody), lenalidomide, and brentuximab vedotin have been incorporated into clinical practice, and several other novel agents are in clinical trials.27Seminars in Hematology. Diagnosis and management of adult T-cell leukemia/lymphoma For the indolent forms (chronic and smoldering), the standard approach remains watchful waiting with regular monitoring until the disease progresses.
Treating HAM/TSP
Managing HAM/TSP is more about slowing progression and controlling symptoms than achieving remission. The mainstay of disease-modifying therapy has been corticosteroids and interferon-alpha, both of which aim to dampen the inflammatory response that damages the spinal cord. Traditional antiretroviral drugs have generally shown limited benefit.28PubMed Central. Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review The most promising emerging therapy is mogamulizumab, the same antibody used in ATL, which targets CCR4-expressing T cells that are heavily infected with HTLV-1. Early results suggest it can reduce the number of infected cells and lower spinal cord inflammation in HAM/TSP patients. Bladder management is a major component of care: catheterization, when necessary, significantly improved bladder symptom scores in the Japanese registry study mentioned earlier, and medications like mirabegron have shown measurable benefit for urinary symptoms.14PubMed Central. Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan No approved vaccine exists for either virus, and vaccine development has been slow compared to HIV, largely because of lower global funding and awareness.
When HIV and HTLV Collide
Because HTLV and HIV share transmission routes, coinfection is not uncommon in areas where both viruses circulate. The combination is worse than either alone. A systematic review found that people coinfected with HIV-1 and HTLV-1 had shorter survival and faster progression to death than those with either virus by itself.29PubMed Central. Clinical and Laboratory Outcomes in HIV-1 and HTLV-1/2 Coinfection: A Systematic Review Paradoxically, coinfected individuals tend to have higher CD4 counts than people with HIV alone, which can create a misleading picture of immune health. They are also more susceptible to a range of opportunistic and inflammatory conditions, including strongyloidiasis (a parasitic infection that can become life-threatening when immunity is compromised), skin diseases, candidiasis, and neurological complications including HAM/TSP. The higher CD4 counts may actually delay the initiation of antiretroviral therapy if clinicians are not aware of the coinfection, which makes screening for HTLV in HIV-positive patients in endemic regions an important but often overlooked step.
Your Genes Help Determine Your Risk
Not everyone infected with HTLV-1 faces the same odds of developing disease. Genetic variation in the immune system, particularly in the HLA genes that help the body recognize and respond to infected cells, plays a measurable role. The class I allele HLA-A*02 halves the odds of developing HAM/TSP and is associated with a proviral load about one-third lower than in carriers without that allele. That single genetic variant is estimated to prevent roughly 28% of potential HAM/TSP cases.30PubMed. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy On the other side, certain HLA alleles increase susceptibility. In an Argentinian population, HLA-B*35 was linked to a higher risk of HAM/TSP, while HLA-C*07 was associated with susceptibility to ATL.31PubMed Central. HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina
Genetic variation in HLA-G, a molecule with a recognized role in dampening immune responses, adds another layer. Certain variants in the HLA-G gene were associated with susceptibility to HTLV-1 infection itself, while others influenced proviral load or the likelihood of progressing to HAM/TSP.32PubMed. HLA-G 3′-untranslated region polymorphisms are associated with HTLV-1 infection, proviral load and HTLV-associated myelopathy/tropical spastic paraparesis development The practical upshot is that proviral load, the amount of HTLV-1 DNA in a carrier’s blood, is strongly shaped by host genetics and is itself one of the strongest predictors of whether disease will develop. Two people infected with the same virus can have wildly different trajectories depending on their immune system’s genetic toolkit.
Where These Viruses Came From
Both HTLV-1 and HTLV-2 originated as zoonotic infections, jumping from nonhuman primates to humans at different points in history. HTLV-1 is closely related to simian T-lymphotropic virus type 1 (STLV-1), found in Old World monkeys and apes across Africa and Asia. Genetic analysis suggests that HTLV-1’s diversity arose from multiple independent cross-species transmission events rather than a single ancient jump.33PubMed Central. Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes HTLV-2 descended separately from STLV-2, confirming that the two human viruses are not simply variants of the same ancestral infection but independent acquisitions from different primate lineages.34PubMed Central. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters The zoonotic risk is not merely historical: studies of central African bushmeat hunters have identified novel primate T-lymphotropic viruses in people with direct contact with nonhuman primates, suggesting that new cross-species jumps continue to occur. Whether any of these newer viral strains could establish human-to-human transmission chains and cause disease remains an open question that virologists are watching.